| Title |
Oncolytic viral therapy for pancreatic cancer: current research and future directions
|
|---|---|
| Published in |
Oncolytic Virotherapy, February 2014
|
| DOI | 10.2147/ov.s53858 |
| Pubmed ID | |
| Authors |
Justin W Ady, Jacqueline Heffner, Elizabeth Klein, Yuman Fong |
| Abstract |
The development of targeted agents and chemotherapies for pancreatic cancer has only modestly affected clinical outcome and not changed 5-year survival. Fortunately the genetic and molecular mechanisms underlying pancreatic cancer are being rapidly uncovered and are providing opportunities for novel targeted therapies. Oncolytic viral therapy is one of the most promising targeted agents for pancreatic cancer. This review will look at the current state of the development of these self-replicating nanoparticles in the treatment of pancreatic cancer. |
Mendeley readers
The data shown below were compiled from readership statistics for 29 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 29 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 7 | 24% |
| Student > Doctoral Student | 4 | 14% |
| Student > Bachelor | 4 | 14% |
| Student > Ph. D. Student | 4 | 14% |
| Student > Master | 3 | 10% |
| Other | 4 | 14% |
| Unknown | 3 | 10% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 6 | 21% |
| Medicine and Dentistry | 6 | 21% |
| Biochemistry, Genetics and Molecular Biology | 5 | 17% |
| Immunology and Microbiology | 3 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 7% |
| Other | 3 | 10% |
| Unknown | 4 | 14% |